Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327547 · ClinicalTrials.gov registry record · Phase 4
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Phase 4 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 138
- Enrollment target
NCT01327547 is a Phase 4 study that has completed, run by ViiV Healthcare. The registered enrollment target is 138 participants.
The verdict
NCT01327547, a Phase 4 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 138 participants
- Enrollment target
Study Summary
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
Interventions
- DRUG Placebo
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2011-05-18 |
| Est. Completion | 2015-03-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327547
The ClinicalTrials.gov registry entry for NCT01327547 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01327547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327547 about?
NCT01327547 is a clinical study titled "A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B". To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
What is the current status of trial NCT01327547?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 138 participants. The study started on 2011-05-18. Estimated completion is 2015-03-24.
What interventions are being tested in trial NCT01327547?
The interventions under investigation include: Placebo (DRUG), Maraviroc (DRUG).
Who is sponsoring clinical trial NCT01327547?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.